Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03709706
Title Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells Specific in NY-ESO-1/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

lung non-small cell carcinoma

Therapies

NY-ESO-1-c259T + Pembrolizumab

NY-ESO-1-c259T

Age Groups: adult | senior
Covered Countries USA | ESP | CAN


No variant requirements are available.